左旋多巴诱导运动波动的预防及治疗进展

摘要/Abstract

摘要： 目的总结国内外关于左旋多巴诱导运动波动症状的研究现状,探讨其临床特点及防治对策。方法对国内外左旋多巴诱导运动波动的相关研究报道进行整理、分析和归纳。结果接受5~10年左旋多巴治疗的患者中,运动并发症的发生率至少为50%。治疗策略包括调整左旋多巴给药方案,联合应用其他辅助药物,特定人群调整蛋白质摄入等。结论目前关于左旋多巴潜在神经保护作用和神经毒性之间仍存在争议,但综合现有证据表明长期应用左旋多巴仍是获益的。

关键词: 帕金森病, 左旋多巴, 运动波动

Abstract: ObjectiveTo summarize researches of levodopa-induced motor fluctuations that were published at home and abroad in recent years, so as to explore the characteristics and management of levodopa-induced motor fluctuations. MethodsStudies about levodopa-induced motor fluctuations were collected, analyzed and summarized. ResultsIt was estimated that motor complications occur in at least 50 percent of patients after 5 to 10 years of levodopa treatment. The main medical strategies were adjusting the levodopa doses and dosing schedule; adding an additional antiparkinson medication; and manipulating dietary protein intake if needed.ConclusionThe debate over the potential neuroprotection versus neurotoxic effects of levodopa remained unresolved, but the weight of the evidence accumulated to date showed that long term use of levodopa was beneficial.

Key words: Parkinson disease, levodopa, motor fluctuation

中图分类号:

R994.11

刘霄, 邓毅. 左旋多巴诱导运动波动的预防及治疗进展[J]. 中国药物警戒, 2017, 14(1): 36-39.

LIU Xiao, DENG Yi. Prevention and Treatment Progress of Levodopa-induced Motor Fluctuations[J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 36-39.

参考文献

[1] Connolly B S, Lang A E. Pharmacological treatment of Parkinson disease: a review [J]. JAMA, 2014, 311(16):1670-1683.
[2] Ferreira J J, Katzenschlager R, Bloem B R, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease [J]. Eur J Neurol, 2013, 1(20):5-15.
[3] Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench- to-bedside gap [J]. Lancet Neurol, 2010, 9(11):1106-1107.
[4] Aquino C C, Fox S H. Clinical spectrum of levodopa-induced complications[J]. Mov Disord, 2015, 30(1):80-89.
[5] Olanow C W, Watts R L, Koller W C. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines [J]. Neurology, 2001, 56(11 Suppl 5):1-88.
[6] Quinn N. Fortnightly Review: Drug treatment of Parkinson’s disease[J]. Bmj Clinical Research, 1995, 310(6979):575-579.
[7] Aquino C C, Fox S H. Clinical Spectrum of Levodopa-Induced Complications [J].Movement Disorders, 2015, 30(1), 80-89.
[8] Muenter M D, Tyce G M. L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects [J]. Mayo Clin Proc, 1971, 46(4):231-239.
[9] Shoulson I, Glaubiger G A, Chase T N. On-off response: clinicaland biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients [J]. Neurology, 1975, 25(12): 1144-1148.
[10] Fahn S. Fluctuations of disability in Parkinson’s disease:pathophysiological aspects. In: Marsden CD, Fahn S, eds. Movement Disorders [M]. London: Butterworth-Heinemann, 1981:123-145.
[11] Merello M, Lees A J. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson’s disease [J]. J Neurol Neurosurg Psychiatry, 1992,55(11): 1024-1026.
[12] Nutt J G, Gancher S T, Woodward W R. Does an inhibitory action of levodopa contribute to motor fluctuations? [J]. Neurology, 1988, 38(10):1553-1557.
[13] Ahlskog J E, Muenter M D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J]. Mov Disord, 2001, 16(3):448-458.
[14] Van Gerpen J A, Kumar N, Bower J H, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990[J]. Arch Neurol, 2006, 63(2):205-209.
[15] Kumar N, Van Gerpen J A, Bower J H, et al. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset [J]. Mov Disord, 2005,20(3):342-344.
[16] Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease [J]. Mov Disord, 2013, 28(8):1064-1071.
[17] Olanow C W, Stern M B, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009) [J]. Neurology, 2009, 72(21 Suppl 4):1-136.
[18] Fahn S, Bressman S B. Should levodopa therapy for Parkinsonism be started early or late? Evidence against early treatment [J]. Can J Neurol Sci, 1984, 11(1 suppl):200-205.
[19] Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease [J]. Arch Neurol, 1986, 43(4):402-405.
[20] Nyholm D, Stepien V. Levodopa fractionation in Parkinson’s disease [J].J Parkinsons Dis, 2014, 4(1):89-96.
[21] Hauser R A, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations:a phase 3 randomised, double-blind trial [J]. Lancet Neurol, 2013,12(4):346-356.
[22] Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients [J]. Parkinsonism Relat Disord, 2014, 20(12):1335-1340.
[23] Pahwa R, Stacy M A, Factor S A, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease [J].Neurology, 2007, 68(14):1108-1115.
[24] LeWitt P A, Lyons K E, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study [J].Neurology, 2007, 68(16):1262-1267.
[25] Schapira A H, Barone P, Hauser R A, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial [J]. Neurology, 2011, 77(8):767-774.
[26] LeWitt P A, Ward C D, Larsen T A, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism [J]. Neurology, 1983,33(8):1009-1014.
[27] Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group [J]. Neurology, 1997, 49(4):1060-1065.
[28] Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson’s disease: a multicenter, crossover,controlled study [J]. Mov Disord, 1994, 9(4):431-436.
[29] Korczyn A D, Brooks D J, Brunt E R, et al. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study[J]. Mov Disord, 1998,13(1):46-51.
[30] Clarke C E, Deane K D. Cabergoline versus bromocriptine for levodopa -induced complications in Parkinson’s disease [J]. Cochrane Database Syst Rev, 2001, (1):CD001519.
[31] Poewe W H, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial [J]. Lancet Neurol,2007, 6(6):513-520.
[32] Pahwa R, Factor S A, Lyons K E, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence -based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [J]. Neurology, 2006, 66(7): 983-995.
[33] Rascol O, Brooks D J, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial [J]. Lancet, 2005, 365(9463):947-954.
[34] Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study [J]. Arch Neurol, 2005, 62 (2):241-248.
[35] Olanow C W, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double -dummy study [J]. Lancet Neurol, 2014, 13(2):141-149.
[36] Fox S H. Non-dopaminergic treatments for motor control in Parkinson’s disease [J]. Drugs, 2013, 73(13):1405-1415.
[37] Murata M, Hasegawa K, Kanazawa I, et al. Japan Zonisamide on PD Study Group. “Zonisamide improves wearing-off in Parkinson’s disease: A randomized, double-blind study”[J]. Mov Disord, 2015, 30(10):1343-1350.
[38] Pourcher E, Huot P. Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson’s Disease [J]. Mov Disord Clin Practice, 2015, 2(4): 331-340.
[39] Metman L V, Slavin K V. Advances in functional neurosurgery for Parkinson’s disease.[J]. Movement Disorders, 2015, 30(11):1461-1470.
[40] Suchowersky O, Gronseth G, Perlmutter J, et al. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [J]. Neurology, 2006, 66(7):976-982.
[41] Tomlinson C L, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease [J]. Cochrane Database of Systematic Reviews, 2012, 11(7):CD002817.
[42] Virmani T, Tazan S, Mazzoni P, et al. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease[J]. J Clin Mov Disord, 2016, 26(3):8.